Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension

2006 ◽  
Vol 7 (9) ◽  
pp. 1133-1138 ◽  
Author(s):  
Rodney Hughes ◽  
Xavier Jais ◽  
Jay Suntharalingam ◽  
Marc Humbert ◽  
Florence Parent ◽  
...  
2007 ◽  
Vol 101 (11) ◽  
pp. 2254-2262 ◽  
Author(s):  
Jay Suntharalingam ◽  
Kimberley Goldsmith ◽  
Mark Toshner ◽  
Natalie Doughty ◽  
Karen K. Sheares ◽  
...  

CHEST Journal ◽  
2013 ◽  
Vol 143 (4) ◽  
pp. 1070-1077 ◽  
Author(s):  
Toshihiko Sugiura ◽  
Nobuhiro Tanabe ◽  
Yukiko Matsuura ◽  
Ayako Shigeta ◽  
Naoko Kawata ◽  
...  

2018 ◽  
Vol 51 (4) ◽  
pp. 1702576 ◽  
Author(s):  
Remedios Otero ◽  
Laurent Bertoletti ◽  
Alfonso Muriel ◽  
Carmine Siniscalchi ◽  
Carmen Jimenez ◽  
...  

2021 ◽  
Vol 16 ◽  
Author(s):  
John G Coghlan ◽  
Alexander MK Rothman ◽  
Stephen P Hoole

Balloon pulmonary angioplasty (BPA) is a novel technique for the treatment of chronic thromboembolic pulmonary hypertension. While cardiologists need no introduction to the concept of balloon angioplasty, BPA has its own particular challenges. This article aims to provide the reader with an overview of BPA, starting with an introduction to chronic thromboembolic disease (CTED), the standard management of chronic thromboembolic pulmonary hypertension (CTEPH), technical challenges faced when performing BPA and the evidence base supporting its use. The second part of the article will focus on the future of BPA, in particular the areas where research is required to establish an evidence base to justify the role of BPA in CTEPH and CTED treatment.


Sign in / Sign up

Export Citation Format

Share Document